Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation-Reference-Cited by-同舟云学术

Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation

Published:2016-01-28 Issue:4 Volume:127 Page:449-457
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Yeomans Alison¹²,Thirdborough Stephen M.¹²,Valle-Argos Beatriz¹²,Linley Adam¹²,Krysov Sergey¹²,Hidalgo Marina Sanchez¹²,Leonard Elodie¹²,Ishfaq Muhammad¹²,Wagner Simon D.³,Willis Anne E.⁴,Steele Andrew J.¹²,Stevenson Freda K.¹²,Forconi Francesco¹²⁵,Coldwell Mark J.⁶,Packham Graham¹²

Affiliation:

1. Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;

2. Experimental Cancer Medicine Centre, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;

3. Department of Cancer Sciences, University of Leicester, Leicester, United Kingdom;

4. Medical Research Council Toxicology Unit, Leicester, United Kingdom;

5. Department of Haematology, University Hospital Southampton National Health Service Trust, Southampton, United Kingdom; and

6. Centre for Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, United Kingdom

Abstract

Key Points BCR stimulation promotes mRNA translation in CLL cells, including of the oncoprotein, MYC, and is inhibited by ibrutinib or tamatinib. Differences in mechanisms of regulation of mRNA translation in CLL and normal blood B cells may highlight potential targets for therapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/4/449/1395326/449.pdf

Reference47 articles.

1. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.;Packham;Haematologica,2014

2. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.;Mockridge;Blood,2007

3. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.;Byrd;N Engl J Med,2013

4. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.;Wiestner;Blood,2012

5. Ibrutinib in B lymphoid malignancies.;Smith;Expert Opin Pharmacother,2015

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic reprogramming in the CLL TME; potential for new therapeutic targets;Seminars in Hematology;2024-06

2. Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects;Cancer Research Communications;2024-05-22

3. ISR inhibition reverses pancreatic β-cell failure in Wolfram syndrome models;Cell Death & Differentiation;2024-02-06

4. Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects;2024-02-03

5. Targeting mRNA translation aberrations: A novel approach for therapy in chronic lymphocytic leukemia;Cancer Communications;2023-10-06